WO2003063610A1 - Oil including omega-3 fatty acids with therapeutic properties - Google Patents

Oil including omega-3 fatty acids with therapeutic properties Download PDF

Info

Publication number
WO2003063610A1
WO2003063610A1 PCT/IB2003/000141 IB0300141W WO03063610A1 WO 2003063610 A1 WO2003063610 A1 WO 2003063610A1 IB 0300141 W IB0300141 W IB 0300141W WO 03063610 A1 WO03063610 A1 WO 03063610A1
Authority
WO
WIPO (PCT)
Prior art keywords
oil
omega
dha
fatty acids
animals
Prior art date
Application number
PCT/IB2003/000141
Other languages
French (fr)
Inventor
Francesc Gasso Casademunt
Original Assignee
Proyecto Empresarial Brudy, S.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto Empresarial Brudy, S.L. filed Critical Proyecto Empresarial Brudy, S.L.
Publication of WO2003063610A1 publication Critical patent/WO2003063610A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/60Fish, e.g. seahorses; Fish eggs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/10Organic substances
    • A23K20/158Fatty acids; Fats; Products containing oils or fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/80Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines

Definitions

  • OIL INCLUDING OMEGA-3 FATTY ACIDS WITH THERAPEUTIC PROPERTIES
  • Thi s invention relates to the use of an acid which include s at least one omega- 3 fatty acid as an antibacterial agent , growth stimulator and anti - coccidiostatic .
  • feeds for animal consumption both in industrial fattening or production and for pet animals (pet foods)
  • growth promoters generally drugs, such as antibiotics, anti-coccidiostatics and others.
  • the objective in use of said products is to maintain an optimum state of health in the animals, in addition to optimizing their growth, production of meat, eggs, etc.
  • the objective of this invention is to solve the disadvantages presented by the use of products such as antibiotics, growth stimulants and anti-coccidiostatics for the fattening of animals.
  • This invention refers to the use of an oil which includes at least one omega-3 fatty acid for non-human animal consumption as a substitute of an antibiotic.
  • said oil acts as an antibacterial agent. In another embodiment of the present invention said oil acts as a growth stimulant agent.
  • said oil acts as an anti-coccidiostatic agent.
  • oils which include omega-3 fatty acids are natural products, so that their addition to the feed achieves a high-quality meat product and does not present the characteristic residues produced when drugs (antibiotic, growth-stimulating factors, etc.) are used.
  • Another advantageous aspect lies in the fact that said acids act to reinforce the immune system, so that as they are not specific to a particular infectious agent
  • oil refers to any oily composition in any of its physical forms.
  • oils such as tuna oil (liquid), whale oil (solid appearance), etc., can be used.
  • animal refers to any animal, and therefore includes both pets and animals which are fed so that all their derivatives are destined to human consumption. Examples of these last animals include rabbits, partridges, sheep, etc.
  • the acid used can be of animal origin, such as from tuna, whale, etc.
  • the oil and/or fat can be of plant origin, such as that from algae.
  • said oils have a high content in omega-3 fatty acids as a result of their treatment by a procedure of concentration.
  • oils which have been submitted to a procedure of concentration of omega-3 fatty acids are called "oils enriched in omega-3 fatty acids”.
  • the concentration of omega-3 fatty acids in the oil ranges from 10-99%, though more preferably between 50 and 99%.
  • Said omega-3 fatty acids can likewise be found chemically modified, as for example in the form of esters of methyl or ethyl or glycerides, among others.
  • the object of this invention is an alternative to the products used (drugs) in the state of the art for the fattening of animals, such as antibiotics, growth stimulants or anti-coccidiostatics.
  • the oil used includes docosahexaenoic acid (Dha) .
  • the oil used includes eicosapentanoic acid (Epa) .
  • the oil of this invention includes a mixture of docosahexaenoic acid and eicosapentanoic acid.
  • the omega-3 fatty acids used according to this invention, and especially Dha and Epa have a high capacity as stimulants of the immune system of animals, permitting fattening of animals without the need to use antibiotics and the like.
  • Another advantageous aspect of this invention is that a meat highly enriched in omega-3 fatty acids is obtained, with the beneficial consequences which said acids involve for the health of people who consume it (such as a reduction of triglycerides in the blood, reduced risk of atherosclerosis, reduction of cardiac problems, etc.).
  • the starting point in this example was 25 batches of 50 animals each, testing different oils with different omega-3 fatty acid compositions.
  • different compositions were supplied at different times over the course of the trial, in order to find which of the fatty acids supplied were the most effective.
  • Another aspect to be determined in this example was to assess the final Dha in the flesh of the animal for human consumption and to evaluate how to avoid the potential undesired effects that might arise from use of an oil with a high index of fish by-products in animal feed, such as the fish flavour in the meat products from animals fed with fish meals or oils.
  • Tuna oil oil with a high Dha content (18% Dha / 7% Epa) .
  • the mothers were initially given daily a feed which included 50 grams of Dha, being observed, within a short time interval, positive effects in the animals, as there were fewer cases of illness and the animals grew normally.
  • the dose of Dha was gradually increased, in such a way that clear beneficial effects began to be observed from 0.200 grams of Dha a day and upwards (in speaking of doses, these are always taken to mean over total Dha or Epa supplied) .
  • Table I shows the results obtained with a group of lambs fed with a commercial feed containing 0.5 g of anti- coccidiostatic, in addition to antibiotics and stimulant factors and the results obtained with a group of lambs fed with a feed to which 0.5 g of Dha had been added.
  • Dha permits the fattening of animals, proving equal to or even more effective than commercial feeds containing a mixture of drugs (anti- coccidiostatics, growth stimulants, etc.), with the consequent advantages possessed by the use of the omega-3 fatty acids.
  • Table II provides a comparison of the results obtained when the animals were given a dose of 1.5 to 2 grams a day, whether of a drug or Dha in the feed, with those obtained when the animals were given a feed to which none of the aforesaid substances had been added.
  • omega-3 fatty acid Dha added in the same quantity as the anti-coccidiostatic results in fattening of the lambs of the same order as that achieved with a commercial feed containing the mixture of drugs, but with the attendant benefits involved in use of Dha instead of any drug, as mentioned above.
  • omega-3 fatty acids permit the fattening of lambs with the same advantages as the stimulants, anti- coccidiostatics and antibiotics usually used to improve growth and meat production in the animals, but with the advantage that the meat is of better quality since it does not contain residues of antibiotics, etc., and is, furthermore, enriched with omega-3 fatty acids, which have beneficial properties for health.
  • Epa Epa
  • Example 2 use of omega-3 fatty acids in other animals
  • the second batch of rabbits was administered a commercial feed containing, among other substances, an anti-coccidiostatic.
  • Both batches had an initial weight of around 650 g live weight.
  • Table IV This table shows a comparison of the effect of a feed to which an anti-coccidiostatic had been added with a feed to which Dha had been added.
  • omega-3 fatty acids can be used for fattening with the above-mentioned advantages in relation to the drugs used for the same purpose (such as antibiotics, etc.) .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Polymers & Plastics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Animal Husbandry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Food Science & Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fodder In General (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Oil comprising at least one omega-3 fatty acid,preferably eicosapentaenoic acid and/or docosahexaenoic acid,for non-human,animal consuption as a subtitute of an antibiotic,as anti-coccidiostatic,as growth stimulating agent and for providing a meat of better quality which is enriched in omega-3 fatty acids.

Description

OIL INCLUDING OMEGA-3 FATTY ACIDS WITH THERAPEUTIC PROPERTIES
FIELD OF THE INVENTION
Thi s invention relates to the use of an acid which include s at least one omega- 3 fatty acid as an antibacterial agent , growth stimulator and anti - coccidiostatic .
BACKGROUND OF THE INVENTION
Usually, most feeds for animal consumption, both in industrial fattening or production and for pet animals (pet foods) , contain growth promoters, generally drugs, such as antibiotics, anti-coccidiostatics and others.
The objective in use of said products is to maintain an optimum state of health in the animals, in addition to optimizing their growth, production of meat, eggs, etc.
For this reason, it is common practice to supply animal feeds to which antibiotics, anti-coccidiostatics, etc., have been added for fattening of the animals, while also preventing the possibility of the animal falling ill (illness being highly probable since the fact that they live in groups makes it easier for infection to spread) . Lamb might be mentioned as an example, that it is characterized by being an animal which presents major health problems during its indoor fattening, for which reason it always needs to eat feed which contains growth stimulants, anti-coccidiostatics or antibiotics. This fact means that the absence of antibiotics and other substances during the fattening periods gives rise to health problems in the animal, leading to weight loss, growth problems, etc., which often shows itself in major economic losses for stockbreeders.
The use of feeds containing such products nevertheless involves the following problems:
(a) The animals receive constant medication included in their food, which is always harmful in itself and because, in the long term, the animals end up developing resistance to the drugs supplied to them, which are then insufficiently effective against microbes, viruses or bacteria.
(b) The possibility that residues of the medication may remain in the meat of these animals, despite periods of suppression being applied, during which such drugs or additives are no longer supplied before the animals are slaughtered.
The objective of this invention is to solve the disadvantages presented by the use of products such as antibiotics, growth stimulants and anti-coccidiostatics for the fattening of animals.
DESCRIPTION OF THE INVENTION
This invention refers to the use of an oil which includes at least one omega-3 fatty acid for non-human animal consumption as a substitute of an antibiotic.
In an embodiment of the present invention, said oil acts as an antibacterial agent. In another embodiment of the present invention said oil acts as a growth stimulant agent.
In yet another embodiment of the present invention, said oil acts as an anti-coccidiostatic agent.
One advantageous aspect of this invention is that the oils which include omega-3 fatty acids are natural products, so that their addition to the feed achieves a high-quality meat product and does not present the characteristic residues produced when drugs (antibiotic, growth-stimulating factors, etc.) are used.
Another advantageous aspect lies in the fact that said acids act to reinforce the immune system, so that as they are not specific to a particular infectious agent
(such as bacteria, etc.) the development of resistance is hindered .
In this invention, the term "oil" refers to any oily composition in any of its physical forms. Thus, for example, oils such as tuna oil (liquid), whale oil (solid appearance), etc., can be used.
In this invention, the term "animal" refers to any animal, and therefore includes both pets and animals which are fed so that all their derivatives are destined to human consumption. Examples of these last animals include rabbits, partridges, sheep, etc.
In a preferred embodiment of this invention, the acid used can be of animal origin, such as from tuna, whale, etc. In another preferred embodiment of this invention, the oil and/or fat can be of plant origin, such as that from algae.
Optionally, said oils have a high content in omega-3 fatty acids as a result of their treatment by a procedure of concentration.
In this invention, oils which have been submitted to a procedure of concentration of omega-3 fatty acids are called "oils enriched in omega-3 fatty acids".
Preferably, the concentration of omega-3 fatty acids in the oil ranges from 10-99%, though more preferably between 50 and 99%.
Said omega-3 fatty acids can likewise be found chemically modified, as for example in the form of esters of methyl or ethyl or glycerides, among others.
Advantageously, the object of this invention is an alternative to the products used (drugs) in the state of the art for the fattening of animals, such as antibiotics, growth stimulants or anti-coccidiostatics.
In a preferred embodiment, the oil used includes docosahexaenoic acid (Dha) .
In another preferred embodiment, the oil used includes eicosapentanoic acid (Epa) .
In yet another preferred embodiment, the oil of this invention includes a mixture of docosahexaenoic acid and eicosapentanoic acid. As mentioned above, the omega-3 fatty acids used according to this invention, and especially Dha and Epa, have a high capacity as stimulants of the immune system of animals, permitting fattening of animals without the need to use antibiotics and the like.
Another advantageous aspect of this invention is that a meat highly enriched in omega-3 fatty acids is obtained, with the beneficial consequences which said acids involve for the health of people who consume it (such as a reduction of triglycerides in the blood, reduced risk of atherosclerosis, reduction of cardiac problems, etc.).
Included below by way of illustrative but non- restrictive example are examples of embodiment of this invention .
EXAMPLES
Example 1: Use of omega-3 fatty acids for fattening lambs
The starting point in this example was 25 batches of 50 animals each, testing different oils with different omega-3 fatty acid compositions. For this purpose different compositions were supplied at different times over the course of the trial, in order to find which of the fatty acids supplied were the most effective.
Another aspect to be determined in this example was to assess the final Dha in the flesh of the animal for human consumption and to evaluate how to avoid the potential undesired effects that might arise from use of an oil with a high index of fish by-products in animal feed, such as the fish flavour in the meat products from animals fed with fish meals or oils.
The following were the oils used:
• Tuna oil: oil with a high Dha content (18% Dha / 7% Epa) .
• Fish oil: 18% Epa and 12% Dha.
• Oil enriched with a minimum Dha content of 50%. • Oil enriched with a minimum Epa content of 50% .
Tests carried out
Merino-type lambs were used, fed with tuna oil (to enrich the feed with Dha) and 18/12 fish oil (18% Epa, 12% Dha) to enrich the feed with Epa. Oils with a high Dha concentration (Dha 50%) were also used for the high enrichments and to study the flavour problems mentioned above .
Early ages: the mothers were fed with Dha by adding tuna oil with a composition of 18% Dha and 6% Epa to the feed, since the young lambs during the first weeks of life would take small quantities and the foundation of their diet was maternal milk.
The mothers were initially given daily a feed which included 50 grams of Dha, being observed, within a short time interval, positive effects in the animals, as there were fewer cases of illness and the animals grew normally. The dose of Dha was gradually increased, in such a way that clear beneficial effects began to be observed from 0.200 grams of Dha a day and upwards (in speaking of doses, these are always taken to mean over total Dha or Epa supplied) . From 10 kg live weight: the lambs began to ingest animal feed regularly, so that the omega-3 fatty acid could be introduced directly into the feed they would consume. Various types of dosages were tried at this age, with beneficial effects being found from a consumption of 50 milligrams a day, whether of Dha or Epa independently, although the best results were obtained for doses equal to or higher than 500 milligrams animal/day. In particular, doses of Dha ranging between 500 milligrams/day and 1 gram/day were administered. The administration of higher doses did not result in a significant increase in the benefits .
During this period 600 lambs were fed, supplying them with a feed at the aforementioned dose of Dha and Epa.
The results obtained are shown in Table I . This table shows the results obtained with a group of lambs fed with a commercial feed containing 0.5 g of anti- coccidiostatic, in addition to antibiotics and stimulant factors and the results obtained with a group of lambs fed with a feed to which 0.5 g of Dha had been added.
Table I. Compara tive resul ts for lambs of 10-18 kg in weight fed wi th 0. 5 g of an anti -coccidiosta tic or wi th Dha
Figure imgf000008_0001
As shown, the use of Dha permits the fattening of animals, proving equal to or even more effective than commercial feeds containing a mixture of drugs (anti- coccidiostatics, growth stimulants, etc.), with the consequent advantages possessed by the use of the omega-3 fatty acids.
From 18 kg live weight: from this age, although beneficial effects are found from 100 milligrams a day of either Dha or Epa, the doses at which most benefit is found are of about 2 grams of Dha daily. Feed containing Dha was given to 1,237 lambs. In parallel to this group, 1,231 lambs wee fattened with feed containing a mixture of anti-coccidiostatic, antibiotics and growth stimulants, while a further 50 lambs were fattened with a feed containing no drug or omega-3 fatty acid.
The results are shown in Table II, which provides a comparison of the results obtained when the animals were given a dose of 1.5 to 2 grams a day, whether of a drug or Dha in the feed, with those obtained when the animals were given a feed to which none of the aforesaid substances had been added.
Table II. Comparative results for lambs of 18-25 kg in weight fed with a feed containing, among other drugs, an anti- coccidiostatic (With Coccid.), or Dha (With Dha) or containing none of those substances (Without Coccid.)
Figure imgf000010_0001
As in the previous case, it was observed that the omega-3 fatty acid Dha added in the same quantity as the anti-coccidiostatic results in fattening of the lambs of the same order as that achieved with a commercial feed containing the mixture of drugs, but with the attendant benefits involved in use of Dha instead of any drug, as mentioned above.
Table III. Sum of the resul ts obtained en Table I and Table II
Figure imgf000011_0001
In the light of the results obtained it is clear that the omega-3 fatty acids permit the fattening of lambs with the same advantages as the stimulants, anti- coccidiostatics and antibiotics usually used to improve growth and meat production in the animals, but with the advantage that the meat is of better quality since it does not contain residues of antibiotics, etc., and is, furthermore, enriched with omega-3 fatty acids, which have beneficial properties for health.
Moreover, as mentioned, the main disadvantage in the use of oils rich in Dha for the fattening of animals is the fish flavour it usually leaves when said oil is used in large doses. This flavour can be so intense as to prevent the sale of such meat. However, the conditions for preventing or overcoming this problem have been optimized as set out below.
(a) By implementing a period of withdrawal of the oil containing the omega-3 fatty acid prior to slaughter, thus reducing this problem significantly or even, depending on the doses used and the length of the period, solving the problem. (b) By using oils enriched up to 70% (in Dha or
Epa) , which can reduce up to three times the amount of oil that must be added to the feed, so that such oils practically eliminate the problem of the flavour in the meat .
Finally, we might note the advantages presented by meat or meat by-products from lamb obtained as described above : (I) Meat that is totally free from residues of antibiotics, stimulants or anti-coccidiostatic, since these were not used during the fattening.
(n) Meat highly enriched in omega-3 fatty acids, with the attendant health benefits for those consuming it. (in) The use of oils with a high concentration of omega-3 fatty acids free from flavours and smells allows the composition of the fatty acids of the meat to be varied. Indeed, with this technique it proved possible to eliminate the typical wool flavour usually possessed by meats and meat by-products of lamb over 25 kg live weight, making the meat milder and suited to the taste of consumers .
Example 2: use of omega-3 fatty acids in other animals
In addition to the trials carried out with lambs, trials were carried out with the following animals.
• Chickens
• Hens
• Rabbits
• Partridge • Calves The same effects and benefits as found with lambs were found in all cases, with particularly significant results with sucking pigs and quail, chickens and rabbits.
Described below are the results obtained in the trial conducted with rabbits.
Trials wi th rabbi ts
Two batches of 1,000 rabbits each were prepared, one being fed with feeds to which oils rich in omega-3 fatty acids had been added, so that the amount of Dha ingested in the feed per rabbit over the twenty days the fattening lasted was 3.5 grams.
The second batch of rabbits was administered a commercial feed containing, among other substances, an anti-coccidiostatic.
Both batches had an initial weight of around 650 g live weight.
The results obtained are shown in Table IV. This table shows a comparison of the effect of a feed to which an anti-coccidiostatic had been added with a feed to which Dha had been added. Table IV
Figure imgf000014_0001
As may be seen from the final results obtained from trials with both feeds, there are practically no significant differences in weight gain, so the omega-3 fatty acids can be used for fattening with the above-mentioned advantages in relation to the drugs used for the same purpose (such as antibiotics, etc.) .

Claims

1. Use of an oil which includes at least one omega-3 fatty acid for non-human animal consumption as a substitute of an antibiotic.
2. Use as claimed claim 1, in which said oil has a high content in an omega-3 fatty acid.
3. Use as claimed in claim 2, in which said oil includes at least one omega-3 fatty acid in a proportion ranging between 10 and 99%.
4. Use as claimed in claim 3, in which said proportion ranges between 50 and 99%.
5. Use as claimed in claim 1 caracterized in that said oil further acts as a growth stimulating agent.
6. Use as claimed in claim 1, characterized in that said oil further acts as an anti-coccidiostatic agent .
7. Use as claimed in any of the preceding claims, in which said oil is of animal origin.
8. Use as claimed in any of the preceding claims
1-8, in which said oil is of plant origin.
9. Use as claimed in any of the preceding claims, in which said oil is added to an animal feed.
10. Use as claimed in Claim 1, characterised in that said omega-3 fatty acid is docosahexaenoic acid.
11. Use as claimed in Claim 1, characterised in that said omega-3 fatty acid is eicosapentanoic acid.
12. Use as claimed in Claim 1, in which said oil includes a mixture of docosahexaenoic acid and eicosapentanoic acid.
13. Use as claimed in claim 1 caracterized in that the quality of meat is improved.
PCT/IB2003/000141 2002-01-29 2003-01-21 Oil including omega-3 fatty acids with therapeutic properties WO2003063610A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP0200188 2002-01-29
ES200200188A ES2195764B1 (en) 2002-01-29 2002-01-29 OIL WITH THERAPEUTIC PROPERTIES.

Publications (1)

Publication Number Publication Date
WO2003063610A1 true WO2003063610A1 (en) 2003-08-07

Family

ID=27635978

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2003/000141 WO2003063610A1 (en) 2002-01-29 2003-01-21 Oil including omega-3 fatty acids with therapeutic properties

Country Status (2)

Country Link
ES (1) ES2195764B1 (en)
WO (1) WO2003063610A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5157596A (en) * 1974-11-12 1976-05-20 Riken Vitamin Oil Co Ltd
JPH04252145A (en) * 1991-01-25 1992-09-08 Riken Vitamin Co Ltd Composition of fats and oils used as feed for culturing fish and feed for culturing fish using the same
US5604258A (en) * 1991-06-24 1997-02-18 Women's And Children's Hospital Adelaide Methods for treating malaria and other diseases
WO1999065327A1 (en) * 1998-06-17 1999-12-23 Dsm N.V. Microbial arachidonic acid (ara) for use in marine feed
US6140365A (en) * 1996-07-22 2000-10-31 Adventis Research & Technologies Gmbh & Co. Kg Preparation of microorganisms comprising omega-3-fatty acid for use as a prophylactic or therapeutic agent against parasitic diseases of animals

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5157596A (en) * 1974-11-12 1976-05-20 Riken Vitamin Oil Co Ltd
JPH04252145A (en) * 1991-01-25 1992-09-08 Riken Vitamin Co Ltd Composition of fats and oils used as feed for culturing fish and feed for culturing fish using the same
US5604258A (en) * 1991-06-24 1997-02-18 Women's And Children's Hospital Adelaide Methods for treating malaria and other diseases
US6140365A (en) * 1996-07-22 2000-10-31 Adventis Research & Technologies Gmbh & Co. Kg Preparation of microorganisms comprising omega-3-fatty acid for use as a prophylactic or therapeutic agent against parasitic diseases of animals
WO1999065327A1 (en) * 1998-06-17 1999-12-23 Dsm N.V. Microbial arachidonic acid (ara) for use in marine feed

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALLEN P C ET AL: "DIETS HIGH IN N-3 FATTY ACIDS REDUCE CECAL LESION SCORES IN CHICKENS INFECTED WITH EIMERIA TENELLA", POULTRY SCIENCE, CHAMPAIGN, IL, US, vol. 75, no. 2, 1 February 1996 (1996-02-01), pages 179 - 185, XP002047882, ISSN: 0032-5791 *
BULLETIN OF THE JAPANESE SOCIETY OF SCIENTIFIC FISHERIES, vol. 42, no. 8, 1976, pages 893 - 906, ISSN: 0021-5392 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1976, WATANABE T ET AL: "EVALUATION OF POLLOCK LIVER OIL AS A SUPPLEMENT TO DIETS FOR RAINBOW TROUT", XP002238580, Database accession no. PREV197763025711 *
DATABASE WPI Section Ch Week 197627, Derwent World Patents Index; Class C03, AN 1976-50872X, XP002238581 *
PATENT ABSTRACTS OF JAPAN vol. 017, no. 030 (C - 1018) 20 January 1993 (1993-01-20) *

Also Published As

Publication number Publication date
ES2195764A1 (en) 2003-12-01
ES2195764B1 (en) 2005-02-01

Similar Documents

Publication Publication Date Title
KR100593965B1 (en) A method for increasing incorporation efficiency of omega-3 highly unsaturated fatty acid in poultry meat
De Keyser et al. Medium‐chain glycerides affect gut morphology, immune‐and goblet cells in post‐weaning piglets: In vitro fatty acid screening with Escherichia coli and in vivo consolidation with LPS challenge
Hasan et al. Benificial effects of probiotic on growth performance and hemato-biochemical parameters in broilers during heat stress
NL1021963C1 (en) Antimicrobial composition for animals.
Ogunwole et al. Performance and carcass characteristics of broiler finishers fed acidifier based diets
JP2013532993A (en) Lauric acid distillate for animal feed
Nagar et al. Influence of dietary supplementation of Shatavari (Asparagus racemosus) and Ashwagandha (Withania somnifera) root powder on feed intake and body weight performance in caged broilers
Akbar et al. Effect of dietary supplementation of salts of organic acids on gut morphology and meat quality of broilers
SI22407A (en) Application of coenzyme q10 for more effective breeding of animals and obtaining animal tissues with increased content of this coenzyme
JPH11514205A (en) Feed or drinking water additives to improve stress resistance and immunity of useful animals
Nagar et al. Impact of dietary supplementation of Shatavari (Asparagus racemosus) and ashwagandha (Withania somnifera) root powder on performances in broilers
NL2000548C1 (en) Rhodospirillum and Phaeospirillum in animal feed for obtaining food products with a lowered cholesterol level.
Gaafar et al. Response of broiler chicken to in ovo administration of nano encapsulated Thyme Oil
Agboola et al. Effects of sodium acetate and sodium propionate supplemented diets on growth performance and gut histomorphology of broiler starters
EP2817016B1 (en) Method for improving quality of poultry meat
WO2003063610A1 (en) Oil including omega-3 fatty acids with therapeutic properties
Abou–Ashour et al. Effect of dietary citric, acetic acids or their mixture on broiler chicks performance, carcass characteristics and some intestinal histomorphological parameters
WO2021099503A1 (en) Animal feed and methods for improving animal performance and productivity
JP2008194001A (en) Fish growth accelerator, feed composition using the same, and method for producing culture fish
JP5009521B2 (en) Animal breeding method
Bawish et al. Effect Of Garlic As Feed Additive On Performance, Carcass Characteristics, And Meat Quality Of Muscovy Ducks Reared In Different Stocking Densities
Živković et al. Garlic as alternative for antibiotics in diet for growing pigs
Morkhade et al. Influence of dietary sodium butyrate supplementation on performance, nutrient digestibility and economics of broiler chicken
Cook The interplay between modern management practices and the chicken: how immune response and the physiological mechanisms for growth and efficiency have adapted over time. Where do we go from here?
Roy et al. Evaluating Organic Acids as Alternatives to Antibiotic Growth Promoters in Enhancing the Performance of Broiler Chicken

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
REG Reference to national code

Ref country code: PT

Ref legal event code: FC4A

Effective date: 20050726

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP